Prof Andrew D Beggs, MBBS, PhD, FRCS is an expert in Digestive surgery at University Hospitals Birmingham NHS Foundation Trust (United Kingdom). Andrew D Beggs has authored 301 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 928 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Andrew D Beggs, MBBS, PhD, FRCS University Hospitals Birmingham NHS Foundation Trust United Kingdom
928 ScienceLeadR Reputation 928
Network Map

Digestive surgery

Subspecialties: Oncology - Surgery - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026

Source: PubMed

University of Birmingham

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 301

Citations

Citations: 11 387 1st author: 28 Last author: 43 Unique author: 5


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insights into the Mechanism of Action of Phosphoantigen Prodrugs on Vγ9Vδ2 T Cell Activation.
PMID 42828364 — cells, neoplasms, work, prodrugs, t-lymphocytes
ACS Pharmacol Transl Sci20260
PBF/PTTG1IP coordinates focal adhesion formation, polarity and cell motility.
PMID 42779963 — cells, tissue adhesions, neoplasms, phenotype, cell adhesion, focal adhesions
bioRxiv20260
The Effect of Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Replacement Therapy on Gut Microbiome Composition in Pancreatic Disease: A Prospective Cohort Study.
PMID 42720994 — cohort studies, pancreas, enzymes, enzyme replacement therapy, therapeutics, bacteria, gastrointestinal microbiome, pancreatic diseases
Pancreas20260
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.
PMID 42714874 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, mutation
Clin Cancer Res20260
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
PMID 42633754 — radiotherapy, organ preservation, neoplasms, aged, chemoradiotherapy, rectal neoplasms, therapeutics
Lancet Oncol Top journal20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 1 1
Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 2
Recruiting 1
Unknown 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 1
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 13

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
NCT06286709 — cholangitis, saline solution, suspensions, multiple chronic conditions, glycerol, enema, inflammatory bowel diseases, cholangitis, sclerosing, transplants, colonoscopy, transplantation, microbiota
Phase 2Recruiting2024

LeadR Networks

Main global connection map